The estimated Net Worth of Aditya Puri is at least 122 千$ dollars as of 9 September 2016. Aditya Puri owns over 1,472,803 units of ViewRay stock worth over 121,919$ and over the last 8 years Aditya sold VRAY stock worth over 0$.
Aditya has made over 1 trades of the ViewRay stock since 2016, according to the Form 4 filled with the SEC. Most recently Aditya bought 1,472,803 units of VRAY stock worth 4,344,769$ on 9 September 2016.
The largest trade Aditya's ever made was buying 1,472,803 units of ViewRay stock on 9 September 2016 worth over 4,344,769$. On average, Aditya trades about 245,467 units every 0 days since 2016. As of 9 September 2016 Aditya still owns at least 4,876,745 units of ViewRay stock.
You can see the complete history of Aditya Puri stock trades at the bottom of the page.
Aditya's mailing address filed with the SEC is C/O VIEWRAY, INC.,, 2 THERMO FISHER WAY, OAKWOOD VILLAGE, OH, 44146.
Over the last 9 years, insiders at ViewRay have traded over 157,178,869$ worth of ViewRay stock and bought 23,644,461 units worth 89,494,703$ . The most active insiders traders include David P Bonita、International Ltd Fosun、Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of 20,317$. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth 1,535$.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: